Natural Product (NP) Details
General Information of the NP (ID: NP9320) | |||||
---|---|---|---|---|---|
Name |
Lithium
|
||||
Synonyms |
7439-93-2; Li; Lithium; litio; UNII-9FN79X2M3F; 9FN79X2M3F; CHEBI:30145; MFCD00134051; Litium; Lithium, metallic; Lithium, elemental; Lithium, 99+%, granular, dry; Lithium compounds; 3Li; HSDB 647; EINECS 231-102-5; UN1415; monolithium; Lithium standard solution, for AAS, 1 mg-ml Li in 2% HCl; Hydrure de lithium [French]; Lithium ribbon; Lithium rod; HSDB 549; Lithium granules; EINECS 231-484-3; UN1414; UN2805; Normothymin-E (TN); Epitope ID:114079; EC 231-102-5; Lithium, 99%, low sodium; Lithium, 99%, high sodium; CHEMBL2146126; DTXSID5036761; HSDB 6900; 7321AH; AKOS015833388; AKOS015902481; HSD6900000; Lithium wire, 3.2mm (0.125in) dia; Lithium [UN1415] [Dangerous when wet]; Lithium granules, 1-6mm (0.04-0.2in); Lithium, granular, 99% trace metals basis; FT-0627905; C15473; D08133; EC 231-484-3; Lithium hydride [UN1414] [Dangerous when wet]; Lithium, shot, 99%, 4-16 mesh, in mineral oil; Lithium, wire, diam. 3.2 mm, in mineral oil, >=98%; Lithium, ~25 wt % dispersion in mineral oil, high sodium; Lithium, AAS standard solution, Specpure?, Li 1000?g/ml; Lithium, ingot, diam. 5.7 cm, 99.9% trace metals basis; Lithium, rod, diam. 12.7 mm, 99.9% trace metals basis; Lithium foil, 0.75mm (0.03in) thick x 19mm (0.75in) wide; Lithium hydride, fused solid [UN2805] [Dangerous when wet]; Lithium ingot, 5.7cm (2.2in) dia x 8.6cm (3.4in) long; Lithium, Oil based standard solution, Specpure, Li 5000g/g; Lithium, plasma standard solution, Specpure?, Li 10,000?g/ml; Lithium, plasma standard solution, Specpure?, Li 1000?g/ml; Lithium, rod, 12.7 mm diameter, length 165 mm, purity 99%; Lithium, rod, 12.7 mm diameter, length 200 mm, purity 99%; Lithium, foil, 25x100mm, thickness 0.6mm, as rolled, 99.9%; Lithium, Oil based standard solution, Specpure(R), Li 1000?g/g; Lithium, foil, thickness 0.6 mm, size 25 x 300 mm, purity 99.9%; Lithium, Ion chromatography standard solution, Specpure, Li+ 1000?g/ml; Lithium, wire (in mineral oil), diam. 3.2 mm, 99.9% trace metals basis; Lithium, foil, not light tested, 38x200mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 38x500mm, thickness 0.20mm, as rolled, 99.9%; Lithium, foil, not light tested, 45x200mm, thickness 0.12mm, as rolled, 99.9%; Lithium, granular, 4-10 mesh particle size, high sodium, 99% (metals basis); Lithium, ribbon, thickness x W 0.38 mm x 23 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 19 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 0.75 mm x 45 mm, 99.9% trace metals basis; Lithium, ribbon, thickness x W 1.5 mm x 100 mm, 99.9% trace metals basis
Click to Show/Hide
|
||||
Disease | Fragile X chromosome [ICD-11: LD55] | Phase 2 | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
Li
|
||||
PubChem CID | |||||
Canonical SMILES |
[Li]
|
||||
InChI |
1S/Li
|
||||
InChIKey |
WHXSMMKQMYFTQS-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 7439-93-2
|
||||
ChEBI ID | |||||
Herb ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Pyrroloquinoline quinone | Osteoporosis | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | p38 beta | Molecule Info |
Pathway MAP
|
|
In-vivo Model | Male APP/PS1 transgenic mice and littermate wild type control were used in this study. | |||||
Experimental
Result(s) |
This study demonstrated the efficacy of a novel AD therapeutic strategy targeting at multiple disease-causing mechanisms through the synergistic effects of microdose lithium and pyrroloquinoline quinone. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Glycogen synthase kinase-3 alpha (GSK-3A) | Molecule Info | [3] | |
Glycogen synthase kinase-3 beta (GSK-3B) | Molecule Info | [3] | ||
KEGG Pathway | ErbB signaling pathway | Click to Show/Hide | ||
2 | Chemokine signaling pathway | |||
3 | Cell cycle | |||
4 | PI3K-Akt signaling pathway | |||
5 | Wnt signaling pathway | |||
6 | Hedgehog signaling pathway | |||
7 | Axon guidance | |||
8 | Hippo signaling pathway | |||
9 | Focal adhesion | |||
10 | Signaling pathways regulating pluripotency of stem cells | |||
11 | T cell receptor signaling pathway | |||
12 | B cell receptor signaling pathway | |||
13 | Neurotrophin signaling pathway | |||
14 | Dopaminergic synapse | |||
15 | Insulin signaling pathway | |||
16 | Melanogenesis | |||
17 | Prolactin signaling pathway | |||
18 | Thyroid hormone signaling pathway | |||
19 | Non-alcoholic fatty liver disease (NAFLD) | |||
20 | Alzheimer's disease | |||
21 | Hepatitis C | |||
22 | Measles | |||
23 | Influenza A | |||
24 | HTLV-I infection | |||
25 | Epstein-Barr virus infection | |||
26 | Pathways in cancer | |||
27 | Colorectal cancer | |||
28 | Endometrial cancer | |||
29 | Prostate cancer | |||
30 | Basal cell carcinoma | |||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | Click to Show/Hide | ||
Panther Pathway | Alzheimer disease-presenilin pathway | Click to Show/Hide | ||
2 | Angiogenesis | |||
3 | Cadherin signaling pathway | |||
4 | Hedgehog signaling pathway | |||
5 | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
6 | Insulin/IGF pathway-protein kinase B signaling cascade | |||
7 | Interleukin signaling pathway | |||
8 | PDGF signaling pathway | |||
9 | PI3 kinase pathway | |||
10 | Wnt signaling pathway | |||
11 | Ras Pathway | |||
12 | CCKR signaling map ST | |||
Pathway Interaction Database | LPA receptor mediated events | Click to Show/Hide | ||
2 | Degradation of beta catenin | |||
3 | Reelin signaling pathway | |||
4 | Presenilin action in Notch and Wnt signaling | |||
5 | Integrin-linked kinase signaling | |||
6 | CDC42 signaling events | |||
7 | LKB1 signaling events | |||
8 | Canonical Wnt signaling pathway | |||
9 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||
10 | Glucocorticoid receptor regulatory network | |||
11 | C-MYC pathway | |||
12 | Regulation of Androgen receptor activity | |||
13 | BMP receptor signaling | |||
14 | Hedgehog signaling events mediated by Gli proteins | |||
15 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
16 | Validated transcriptional targets of deltaNp63 isoforms | |||
17 | Aurora A signaling | |||
18 | Insulin-mediated glucose transport | |||
19 | Class I PI3K signaling events mediated by Akt | |||
20 | p53 pathway | |||
21 | Trk receptor signaling mediated by PI3K and PLC-gamma | |||
22 | FOXM1 transcription factor network | |||
Reactome | Degradation of beta-catenin by the destruction complex | Click to Show/Hide | ||
2 | AKT phosphorylates targets in the cytosol | |||
3 | Regulation of HSF1-mediated heat shock response | |||
4 | CRMPs in Sema3A signaling | |||
5 | Disassembly of the destruction complex and recruitment of AXIN to the membrane | |||
6 | S33 mutants of beta-catenin aren't phosphorylated | |||
7 | S37 mutants of beta-catenin aren't phosphorylated | |||
8 | S45 mutants of beta-catenin aren't phosphorylated | |||
9 | T41 mutants of beta-catenin aren't phosphorylated | |||
10 | Degradation of GLI2 by the proteasome | |||
11 | Constitutive Signaling by AKT1 E17K in Cancer | |||
12 | XBP1(S) activates chaperone genes | |||
WikiPathways | DNA Damage Response (only ATM dependent) | Click to Show/Hide | ||
2 | Senescence and Autophagy in Cancer | |||
3 | Notch Signaling Pathway | |||
4 | Glycogen Metabolism | |||
5 | Insulin Signaling | |||
6 | Wnt Signaling Pathway | |||
7 | Wnt Signaling Pathway and Pluripotency | |||
8 | IL-6 signaling pathway | |||
9 | Wnt Signaling Pathway Netpath | |||
10 | Copper homeostasis | |||
11 | Focal Adhesion | |||
12 | Hair Follicle Development: Induction (Part 1 of 3) | |||
13 | Cardiac Hypertrophic Response | |||
14 | Degradation of beta-catenin by the destruction complex | |||
15 | T-Cell Receptor and Co-stimulatory Signaling | |||
16 | Cardiac Progenitor Differentiation | |||
17 | BDNF signaling pathway | |||
18 | Corticotropin-releasing hormone | |||
19 | B Cell Receptor Signaling Pathway | |||
20 | IL17 signaling pathway | |||
21 | Neural Crest Differentiation | |||
22 | Alzheimers Disease | |||
23 | IL-7 Signaling Pathway | |||
24 | Regulation of Microtubule Cytoskeleton | |||
25 | TWEAK Signaling Pathway | |||
26 | Leptin signaling pathway | |||
27 | Semaphorin interactions | |||
28 | Cell Cycle | |||
29 | MicroRNAs in cardiomyocyte hypertrophy | |||
30 | Androgen receptor signaling pathway | |||
31 | IL-5 Signaling Pathway |
